首页> 外文OA文献 >Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy
【2h】

Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy

机译:根除幽门螺杆菌对奥美拉唑治疗期间慢性胃炎的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND—We have previously observed that profound acid suppressive therapy in Helicobacter pylori positive patients with gastro-oesophageal reflux disease is associated with increased corpus inflammation and accelerated development of atrophic gastritis.
AIM—To investigate if H pylori eradication at the start of acid suppressive therapy prevents the development of these histological changes.
PATIENTS/METHODS—In a prospective randomised case control study, patients with reflux oesophagitis were treated with omeprazole 40 mg once daily for 12 months. H pylori positive patients were randomised to additional double blind treatment with omeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg twice daily or placebo for one week. Biopsy sampling for histology, scored according to the updated Sydney classification, and culture were performed at baseline, and at three and 12 months.
RESULTS—In the persistently H pylori positive group (n=24), active inflammation increased in the corpus and decreased in the antrum during therapy (p=0.032 and p=0.002, respectively). In contrast, in the H pylori positive group that became H pylori negative as a result of treatment (n=33), active and chronic inflammation in both the corpus and antrum decreased (p⩽0.0001). The decrease in active and chronic inflammation in the corpus differed significantly compared with the persistently H pylori positive group (both p=0.001). For atrophy scores, no significant differences were observed between H pylori eradicated and persistently H pylori positive patients within one year of follow up. No changes were observed in the H pylori negative control group (n=26).
CONCLUSIONS—H pylori eradication prevents the increase in corpus gastritis associated with profound acid suppressive therapy. Longer follow up is needed to determine if H pylori eradication prevents the development of atrophic gastritis.


Keywords: Helicobacter pylori; gastritis; omeprazole; atropy; gastro-oesophageal reflux disease
机译:背景—我们以前曾观察到幽门螺杆菌阳性胃食管反流病患者的强酸抑制疗法与体炎症增加和萎缩性胃炎的发展有关。目的—研究在抑酸治疗开始时是否根除幽门螺杆菌会阻止这些组织学改变的发展。患者/方法-在一项前瞻性随机病例对照研究中,患有反流性食管炎的患者每天用奥美拉唑40毫克治疗一次,持续12个月。幽门螺杆菌阳性患者随机分为两组,分别每日两次奥美拉唑20 mg,阿莫西林1000 mg和克拉霉素500 mg进行双盲治疗或安慰剂治疗1周。组织学活检取样,根据最新的悉尼分类评分,并在基线,三个月和十二个月进行培养。结果:在持续的幽门螺杆菌阳性组(n = 24)中,治疗期间活动性炎症在体中增加而在胃窦中减少(分别为p = 0.032和p = 0.002)。相反,在由于治疗而变为幽门螺杆菌阴性的幽门螺杆菌阳性组中(n = 33),体和胃窦的活动性和慢性炎症均降低(p⩽0.0001)。与持续性幽门螺杆菌阳性组相比,全体内活动性炎症和慢性炎症的减少有显着差异(均为p = 0.001)。对于萎缩评分,在随访的一年内,根除幽门螺杆菌和持续幽门螺杆菌阳性患者之间没有观察到显着差异。在幽门螺杆菌阴性对照组中未观察到变化(n = 26)。结论—根除幽门螺杆菌可预防与深度酸抑制疗法相关的胃炎胃炎的增加。需要更长的随访时间来确定根除幽门螺杆菌是否可以预防萎缩性胃炎的发展。关键词:幽门螺杆菌;胃炎;奥美拉唑熵胃食管反流病

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号